person · Reporting owner

Lundberg Sven Ante

Disclosed activity across 5 companies

Tapewire entity: 27986
SEC CIK: 0001682126

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
CRISPR Therapeutics AGCRSP · Entity 3852	Chief Scientific Officer	October 24, 2016	February 10, 2017
Q32 Bio Inc.QTTB · Entity 5594	Director	June 12, 2026	July 22, 2026
Vor Biopharma Inc.VOR · Entity 4763	Director	May 22, 2025	May 23, 2025
Yarrow Bioscience, Inc.YARW · Entity 6871	Director	July 27, 2026	July 30, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CRISPR Therapeutics AG

Report date October 24, 2016 · Filed February 10, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common SharesSEC Table I · non-derivative	Direct	505,217	Reported balance After 2016-10-24 transaction · row 1 1 source row Row 1 · 2016-10-24 · Conversion · Acquired 55,217 · Balance 505,217 F1: These securities were convertible at any time on a one-for-one basis into shares of the Issuer's Common Stock at the holder's election and automatically upon the closing of the Issuer's initial public offering. These securities do not have an expiration date.
Common SharesSEC Table I · non-derivative	IndirectBy wife	505,617	Reported balance After 2016-10-24 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2016-10-24 · Purchase · Acquired 400 · Balance 505,617
Series B Preferred SharesSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	0	Reported balance After 2016-10-24 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2016-10-24 · Conversion · Disposed 55,217 · Balance 0 F1: These securities were convertible at any time on a one-for-one basis into shares of the Issuer's Common Stock at the holder's election and automatically upon the closing of the Issuer's initial public offering. These securities do not have an expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: These securities were convertible at any time on a one-for-one basis into shares of the Issuer's Common Stock at the holder's election and automatically upon the closing of the Issuer's initial public offering. These securities do not have an expiration date.

Q32 Bio Inc.

Report date June 12, 2026 · Filed July 22, 2026 · Amendment

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.64 · Expires 2036-06-11	Direct	10,826	Reported balance After 2026-06-12 transaction · row 1 Amendment: may correct only part of an earlier disclosure. 1 source row Row 1 · 2026-06-12 · Grant · Acquired 10,826 · Balance 10,826 F1: This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026. F2: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026.

F2: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

Vor Biopharma Inc.

Report date May 22, 2025 · Filed May 23, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.19 · Expires 2035-05-21	Direct	30,000	Reported balance After 2025-05-22 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-05-22 · Grant · Acquired 30,000 · Balance 30,000 F1: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) May 22, 2026 or (ii) the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date.

Filing footnotes · ownership attribution and instrument terms

F1: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) May 22, 2026 or (ii) the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date.

Yarrow Bioscience, Inc.

Report date July 27, 2026 · Filed July 30, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.19 · Expires 2036-04-17	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-07-27 · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · Balance Not disclosed F1: Effective as of July 27, 2026 (the "Effective Time"), a wholly owned subsidiary of VYNE Therapeutics Inc. ("VYNE") merged with and into Yarrow Bioscience, Inc. ("Yarrow") with Yarrow continuing as a wholly owned subsidiary of VYNE and the surviving corporation of the merger (the "Merger") under the name "Yarrow Bioscience Operating Company Corp." In connection with the completion of the Merger, VYNE changed its name to "Yarrow Bioscience, Inc." (hereinafter, the "Issuer"). F2: Represents options to purchase shares of common stock, par value $0.0001, of the Issuer ("Issuer Common Stock") received by the Reporting Person in the Merger in exchange for options to purchase shares of common stock of Yarrow held by the Reporting Person prior to the Merger. At the Effective Time, the Issuer assumed each such Yarrow option, whether vested or unvested, and converted it into an option to purchase shares of Issuer Common Stock on the same terms and conditions as were in effect immediately prior to the Effective Time. F3: This option represents a right to purchase 175,639 shares of Issuer Common Stock, one quarter of which will vest on April 17, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Effective as of July 27, 2026 (the "Effective Time"), a wholly owned subsidiary of VYNE Therapeutics Inc. ("VYNE") merged with and into Yarrow Bioscience, Inc. ("Yarrow") with Yarrow continuing as a wholly owned subsidiary of VYNE and the surviving corporation of the merger (the "Merger") under the name "Yarrow Bioscience Operating Company Corp." In connection with the completion of the Merger, VYNE changed its name to "Yarrow Bioscience, Inc." (hereinafter, the "Issuer").

F2: Represents options to purchase shares of common stock, par value $0.0001, of the Issuer ("Issuer Common Stock") received by the Reporting Person in the Merger in exchange for options to purchase shares of common stock of Yarrow held by the Reporting Person prior to the Merger. At the Effective Time, the Issuer assumed each such Yarrow option, whether vested or unvested, and converted it into an option to purchase shares of Issuer Common Stock on the same terms and conditions as were in effect immediately prior to the Effective Time.

F3: This option represents a right to purchase 175,639 shares of Issuer Common Stock, one quarter of which will vest on April 17, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Merus N.V.

Report date December 12, 2025 · Filed December 12, 2025

Section 16 reporting ended · disclosed 2025-12-12. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common SharesSEC Table I · non-derivative	IndirectAnte S Lundberg Qualified Annuity Interest Trust XI	Reported balance After 2025-12-12 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2025-12-12 · Other · Disposed 30,297 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time, including the Shares tendered by the reporting person, in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: The indirect holdings represent shares for which the Reporting Person and members of his immediate family are the sole beneficiaries.
Common SharesSEC Table I · non-derivative	IndirectAnte S Lundberg Qualified Annuity Int Trust X	Reported balance After 2025-12-12 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2025-12-12 · Other · Disposed 16,372 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time, including the Shares tendered by the reporting person, in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: The indirect holdings represent shares for which the Reporting Person and members of his immediate family are the sole beneficiaries.
Common SharesSEC Table I · non-derivative	IndirectKatrina Lundberg 2018 Irrevocable Trust	Reported balance After 2025-12-12 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2025-12-12 · Other · Disposed 9,191 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time, including the Shares tendered by the reporting person, in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: The indirect holdings represent shares for which the Reporting Person and members of his immediate family are the sole beneficiaries.
Common SharesSEC Table I · non-derivative	IndirectMadeleine Lundberg 2018 Irrevocable Trust	Reported balance After 2025-12-12 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2025-12-12 · Other · Disposed 9,191 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time, including the Shares tendered by the reporting person, in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: The indirect holdings represent shares for which the Reporting Person and members of his immediate family are the sole beneficiaries.
Common SharesSEC Table I · non-derivative	IndirectKristian Ante Lundberg 2018 Irrevocable Trust	Reported balance After 2025-12-12 transaction · row 5 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 5 · 2025-12-12 · Other · Disposed 9,192 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time, including the Shares tendered by the reporting person, in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: The indirect holdings represent shares for which the Reporting Person and members of his immediate family are the sole beneficiaries.
Common SharesSEC Table I · non-derivative	IndirectEmily Lundberg 2018 Irrevocable Trust	Reported balance After 2025-12-12 transaction · row 6 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 6 · 2025-12-12 · Other · Disposed 9,192 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time, including the Shares tendered by the reporting person, in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: The indirect holdings represent shares for which the Reporting Person and members of his immediate family are the sole beneficiaries.
Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.52 · Expires 2030-01-03	Direct	Reported balance After 2025-12-12 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2025-12-12 · Disposition to issuer · Disposed 312,620 · Balance 0 F3: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.
Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.43 · Expires 2031-02-16	Direct	Reported balance After 2025-12-12 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2025-12-12 · Disposition to issuer · Disposed 351,628 · Balance 0 F3: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.
Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.65 · Expires 2035-01-29	Direct	Reported balance After 2025-12-12 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2025-12-12 · Disposition to issuer · Disposed 300,000 · Balance 0 F3: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.
Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.09 · Expires 2034-01-31	Direct	Reported balance After 2025-12-12 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2025-12-12 · Disposition to issuer · Disposed 360,000 · Balance 0 F3: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.
Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.07 · Expires 2033-02-02	Direct	Reported balance After 2025-12-12 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2025-12-12 · Disposition to issuer · Disposed 380,000 · Balance 0 F3: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.
Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.61 · Expires 2032-01-31	Direct	Reported balance After 2025-12-12 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2025-12-12 · Disposition to issuer · Disposed 295,000 · Balance 0 F3: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.

Filing footnotes · ownership attribution and instrument terms

F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time, including the Shares tendered by the reporting person, in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time.

F2: The indirect holdings represent shares for which the Reporting Person and members of his immediate family are the sole beneficiaries.

F3: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 12, 2026 Filed Jun 16, 2026 20:30 UTC	Q32 Bio Inc. QTTB · Entity 5594	GrantStock Option (Right to Buy) · Derivative	9,810	$0.00 Strike: $12.64	$0.00	Disclosure SEC source: 0001193125-26-272684 · ownership.xml · derivative · entry 1 Lundberg Sven Ante · CIK 0001682126 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,810 Underlying: Common Stock · 9,810 shares Expires 2036-06-11 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. Read SEC document
June 12, 2026 Filed Jul 22, 2026 00:39 UTC Amendment	Q32 Bio Inc. QTTB · Entity 5594	GrantStock Option (Right to Buy) · Derivative	10,826	$0.00 Strike: $12.64	$0.00	Disclosure SEC source: 0001193125-26-310982 · ownership.xml · derivative · entry 1 Lundberg Sven Ante · CIK 0001682126 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,826 Underlying: Common Stock · 10,826 shares Expires 2036-06-11 F1 · shares: This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026. F2 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. F1 · derivative.underlying_shares: This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026. F1 · balance_after: This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026. Read SEC document
January 15, 2026 Filed Jan 31, 2026 00:00 UTC	Q32 Bio Inc. QTTB · Entity 5594	GrantStock Option (Right to Buy) · Derivative	20,363	$2.75 Strike: $3.60	$55,998.25	Disclosure SEC source: 0001193125-26-032246 · ownership.xml · derivative · entry 1 Lundberg Sven Ante · CIK 0001682126 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,363 Underlying: Common Stock · 20,363 shares Expires 2036-01-14 F1 · price: This option was granted to the Reporting Person, a director of the Issuer pursuant to the 2024 Stock Option and Incentive Plan and pursuant to the Issuer's non-employee director compensation policy. This option shall vest in four equal quarterly installments as of the last date of each calendar quarter subject to the Reporting Person's continued service through such date and represents the Reporting Person's election to receive stock options in lieu of cash retainer fees. Due to administrative oversight this option award initially was not reported. F1 · derivative.exercise_date: This option was granted to the Reporting Person, a director of the Issuer pursuant to the 2024 Stock Option and Incentive Plan and pursuant to the Issuer's non-employee director compensation policy. This option shall vest in four equal quarterly installments as of the last date of each calendar quarter subject to the Reporting Person's continued service through such date and represents the Reporting Person's election to receive stock options in lieu of cash retainer fees. Due to administrative oversight this option award initially was not reported. Read SEC document
December 12, 2025 Filed Dec 12, 2025 18:59 UTC	Merus N.V. MRUS · Entity 70740	Disposition to issuerShare Option (right to buy) · Derivative	295,000	$0.00 Strike: $24.61	$0.00	Disclosure SEC source: 0001193125-25-317947 · ownership.xml · derivative · entry 12 Lundberg Sven Ante · CIK 0001682126 · Director · President, CEO & PEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 295,000 shares Expires 2032-01-31 F3 · derivative.exercise_date: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. Read SEC document
December 12, 2025 Filed Dec 12, 2025 18:59 UTC	Merus N.V. MRUS · Entity 70740	Disposition to issuerShare Option (right to buy) · Derivative	380,000	$0.00 Strike: $16.07	$0.00	Disclosure SEC source: 0001193125-25-317947 · ownership.xml · derivative · entry 11 Lundberg Sven Ante · CIK 0001682126 · Director · President, CEO & PEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 380,000 shares Expires 2033-02-02 F3 · derivative.exercise_date: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. Read SEC document
December 12, 2025 Filed Dec 12, 2025 18:59 UTC	Merus N.V. MRUS · Entity 70740	Disposition to issuerShare Option (right to buy) · Derivative	360,000	$0.00 Strike: $36.09	$0.00	Disclosure SEC source: 0001193125-25-317947 · ownership.xml · derivative · entry 10 Lundberg Sven Ante · CIK 0001682126 · Director · President, CEO & PEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 360,000 shares Expires 2034-01-31 F3 · derivative.exercise_date: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. Read SEC document
December 12, 2025 Filed Dec 12, 2025 18:59 UTC	Merus N.V. MRUS · Entity 70740	Disposition to issuerShare Option (right to buy) · Derivative	300,000	$0.00 Strike: $41.65	$0.00	Disclosure SEC source: 0001193125-25-317947 · ownership.xml · derivative · entry 9 Lundberg Sven Ante · CIK 0001682126 · Director · President, CEO & PEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 300,000 shares Expires 2035-01-29 F3 · derivative.exercise_date: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. Read SEC document
December 12, 2025 Filed Dec 12, 2025 18:59 UTC	Merus N.V. MRUS · Entity 70740	Disposition to issuerShare Option (right to buy) · Derivative	351,628	$0.00 Strike: $24.43	$0.00	Disclosure SEC source: 0001193125-25-317947 · ownership.xml · derivative · entry 8 Lundberg Sven Ante · CIK 0001682126 · Director · President, CEO & PEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 351,628 shares Expires 2031-02-16 F3 · derivative.exercise_date: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. Read SEC document
December 12, 2025 Filed Dec 12, 2025 18:59 UTC	Merus N.V. MRUS · Entity 70740	Disposition to issuerShare Option (right to buy) · Derivative	312,620	$0.00 Strike: $13.52	$0.00	Disclosure SEC source: 0001193125-25-317947 · ownership.xml · derivative · entry 7 Lundberg Sven Ante · CIK 0001682126 · Director · President, CEO & PEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 312,620 shares Expires 2030-01-03 F3 · derivative.exercise_date: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. Read SEC document
December 12, 2025 Filed Dec 12, 2025 18:59 UTC	Merus N.V. MRUS · Entity 70740	OtherCommon Shares	9,192	$97.00	$891,624.00	Disclosure SEC source: 0001193125-25-317947 · ownership.xml · nonDerivative · entry 6 Lundberg Sven Ante · CIK 0001682126 · Director · President, CEO & PEO 10b5-1 filing: No plan indicated Ownership: Indirect · Emily Lundberg 2018 Irrevocable Trust Disclosed balance after: 0 F1 · price: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time, including the Shares tendered by the reporting person, in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2 · ownership.nature: The indirect holdings represent shares for which the Reporting Person and members of his immediate family are the sole beneficiaries. Read SEC document
December 12, 2025 Filed Dec 12, 2025 18:59 UTC	Merus N.V. MRUS · Entity 70740	OtherCommon Shares	9,192	$97.00	$891,624.00	Disclosure SEC source: 0001193125-25-317947 · ownership.xml · nonDerivative · entry 5 Lundberg Sven Ante · CIK 0001682126 · Director · President, CEO & PEO 10b5-1 filing: No plan indicated Ownership: Indirect · Kristian Ante Lundberg 2018 Irrevocable Trust Disclosed balance after: 0 F1 · price: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time, including the Shares tendered by the reporting person, in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2 · ownership.nature: The indirect holdings represent shares for which the Reporting Person and members of his immediate family are the sole beneficiaries. Read SEC document
December 12, 2025 Filed Dec 12, 2025 18:59 UTC	Merus N.V. MRUS · Entity 70740	OtherCommon Shares	9,191	$97.00	$891,527.00	Disclosure SEC source: 0001193125-25-317947 · ownership.xml · nonDerivative · entry 4 Lundberg Sven Ante · CIK 0001682126 · Director · President, CEO & PEO 10b5-1 filing: No plan indicated Ownership: Indirect · Madeleine Lundberg 2018 Irrevocable Trust Disclosed balance after: 0 F1 · price: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time, including the Shares tendered by the reporting person, in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2 · ownership.nature: The indirect holdings represent shares for which the Reporting Person and members of his immediate family are the sole beneficiaries. Read SEC document
December 12, 2025 Filed Dec 12, 2025 18:59 UTC	Merus N.V. MRUS · Entity 70740	OtherCommon Shares	9,191	$97.00	$891,527.00	Disclosure SEC source: 0001193125-25-317947 · ownership.xml · nonDerivative · entry 3 Lundberg Sven Ante · CIK 0001682126 · Director · President, CEO & PEO 10b5-1 filing: No plan indicated Ownership: Indirect · Katrina Lundberg 2018 Irrevocable Trust Disclosed balance after: 0 F1 · price: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time, including the Shares tendered by the reporting person, in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2 · ownership.nature: The indirect holdings represent shares for which the Reporting Person and members of his immediate family are the sole beneficiaries. Read SEC document
December 12, 2025 Filed Dec 12, 2025 18:59 UTC	Merus N.V. MRUS · Entity 70740	OtherCommon Shares	16,372	$97.00	$1,588,084.00	Disclosure SEC source: 0001193125-25-317947 · ownership.xml · nonDerivative · entry 2 Lundberg Sven Ante · CIK 0001682126 · Director · President, CEO & PEO 10b5-1 filing: No plan indicated Ownership: Indirect · Ante S Lundberg Qualified Annuity Int Trust X Disclosed balance after: 0 F1 · price: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time, including the Shares tendered by the reporting person, in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2 · ownership.nature: The indirect holdings represent shares for which the Reporting Person and members of his immediate family are the sole beneficiaries. Read SEC document
December 12, 2025 Filed Dec 12, 2025 18:59 UTC	Merus N.V. MRUS · Entity 70740	OtherCommon Shares	30,297	$97.00	$2,938,809.00	Disclosure SEC source: 0001193125-25-317947 · ownership.xml · nonDerivative · entry 1 Lundberg Sven Ante · CIK 0001682126 · Director · President, CEO & PEO 10b5-1 filing: No plan indicated Ownership: Indirect · Ante S Lundberg Qualified Annuity Interest Trust XI Disclosed balance after: 0 F1 · price: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time, including the Shares tendered by the reporting person, in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2 · ownership.nature: The indirect holdings represent shares for which the Reporting Person and members of his immediate family are the sole beneficiaries. Read SEC document
November 25, 2025 Filed Nov 28, 2025 16:30 UTC	Merus N.V. MRUS · Entity 70740	GiftCommon Shares	2,539	$0.00	$0.00	Disclosure SEC source: 0001193125-25-302579 · ownership.xml · nonDerivative · entry 11 Lundberg Sven Ante · CIK 0001682126 · Director · President, CEO & PEO 10b5-1 filing: No plan indicated Ownership: Indirect · Emily Lundberg 2018 Irrevocable Trust Disclosed balance after: 9,192 F1 · ownership.nature: The indirect holdings represent shares for which the Reporting Person and members of his immediate family are the sole beneficiaries. Read SEC document
November 25, 2025 Filed Nov 28, 2025 16:30 UTC	Merus N.V. MRUS · Entity 70740	GiftCommon Shares	2,539	$0.00	$0.00	Disclosure SEC source: 0001193125-25-302579 · ownership.xml · nonDerivative · entry 10 Lundberg Sven Ante · CIK 0001682126 · Director · President, CEO & PEO 10b5-1 filing: No plan indicated Ownership: Indirect · Kristian Ante Lundberg 2018 Irrevocable Trust Disclosed balance after: 9,192 F1 · ownership.nature: The indirect holdings represent shares for which the Reporting Person and members of his immediate family are the sole beneficiaries. Read SEC document
November 25, 2025 Filed Nov 28, 2025 16:30 UTC	Merus N.V. MRUS · Entity 70740	GiftCommon Shares	2,539	$0.00	$0.00	Disclosure SEC source: 0001193125-25-302579 · ownership.xml · nonDerivative · entry 9 Lundberg Sven Ante · CIK 0001682126 · Director · President, CEO & PEO 10b5-1 filing: No plan indicated Ownership: Indirect · Madeleine Lundberg 2018 Irrevocable Trust Disclosed balance after: 9,191 F1 · ownership.nature: The indirect holdings represent shares for which the Reporting Person and members of his immediate family are the sole beneficiaries. Read SEC document
November 25, 2025 Filed Nov 28, 2025 16:30 UTC	Merus N.V. MRUS · Entity 70740	GiftCommon Shares	2,538	$0.00	$0.00	Disclosure SEC source: 0001193125-25-302579 · ownership.xml · nonDerivative · entry 8 Lundberg Sven Ante · CIK 0001682126 · Director · President, CEO & PEO 10b5-1 filing: No plan indicated Ownership: Indirect · Katrina Lundberg 2018 Irrevocable Trust Disclosed balance after: 9,191 F1 · ownership.nature: The indirect holdings represent shares for which the Reporting Person and members of his immediate family are the sole beneficiaries. Read SEC document
November 25, 2025 Filed Nov 28, 2025 16:30 UTC	Merus N.V. MRUS · Entity 70740	GiftCommon Shares	24,229	$0.00	$0.00	Disclosure SEC source: 0001193125-25-302579 · ownership.xml · nonDerivative · entry 7 Lundberg Sven Ante · CIK 0001682126 · Director · President, CEO & PEO 10b5-1 filing: No plan indicated Ownership: Indirect · Ante S Lundberg Qualified Annuity Int Trust X Disclosed balance after: 16,372 F1 · ownership.nature: The indirect holdings represent shares for which the Reporting Person and members of his immediate family are the sole beneficiaries. Read SEC document
November 25, 2025 Filed Nov 28, 2025 16:30 UTC	Merus N.V. MRUS · Entity 70740	GiftCommon Shares	22,449	$0.00	$0.00	Disclosure SEC source: 0001193125-25-302579 · ownership.xml · nonDerivative · entry 6 Lundberg Sven Ante · CIK 0001682126 · Director · President, CEO & PEO 10b5-1 filing: No plan indicated Ownership: Indirect · Ante Sven Lundberg Qualified Annuity Interest Trust IX Disclosed balance after: 0 F1 · ownership.nature: The indirect holdings represent shares for which the Reporting Person and members of his immediate family are the sole beneficiaries. Read SEC document
November 25, 2025 Filed Nov 28, 2025 16:30 UTC	Merus N.V. MRUS · Entity 70740	GiftCommon Shares	52,369	$0.00	$0.00	Disclosure SEC source: 0001193125-25-302579 · ownership.xml · nonDerivative · entry 5 Lundberg Sven Ante · CIK 0001682126 · Director · President, CEO & PEO 10b5-1 filing: No plan indicated Ownership: Indirect · Ante Sven Lundberg Qualified Annuity Interest Trust VIII Disclosed balance after: 0 F1 · ownership.nature: The indirect holdings represent shares for which the Reporting Person and members of his immediate family are the sole beneficiaries. Read SEC document
November 25, 2025 Filed Nov 28, 2025 16:30 UTC	Merus N.V. MRUS · Entity 70740	GiftCommon Shares	12,215	$0.00	$0.00	Disclosure SEC source: 0001193125-25-302579 · ownership.xml · nonDerivative · entry 4 Lundberg Sven Ante · CIK 0001682126 · Director · President, CEO & PEO 10b5-1 filing: No plan indicated Ownership: Indirect · Ante S Lundberg Qualified Annuity Int Trust VII Disclosed balance after: 0 F1 · ownership.nature: The indirect holdings represent shares for which the Reporting Person and members of his immediate family are the sole beneficiaries. Read SEC document
November 25, 2025 Filed Nov 28, 2025 16:30 UTC	Merus N.V. MRUS · Entity 70740	GiftCommon Shares	14,198	$0.00	$0.00	Disclosure SEC source: 0001193125-25-302579 · ownership.xml · nonDerivative · entry 3 Lundberg Sven Ante · CIK 0001682126 · Director · President, CEO & PEO 10b5-1 filing: No plan indicated Ownership: Indirect · Ante Sven Lundberg Qualified Annuity Interest Trust VI Disclosed balance after: 0 F1 · ownership.nature: The indirect holdings represent shares for which the Reporting Person and members of his immediate family are the sole beneficiaries. Read SEC document
November 25, 2025 Filed Nov 28, 2025 16:30 UTC	Merus N.V. MRUS · Entity 70740	GiftCommon Shares	30,297	$0.00	$0.00	Disclosure SEC source: 0001193125-25-302579 · ownership.xml · nonDerivative · entry 2 Lundberg Sven Ante · CIK 0001682126 · Director · President, CEO & PEO 10b5-1 filing: No plan indicated Ownership: Indirect · Ante S Lundberg Qualified Annuity Interest Trust XI Disclosed balance after: 30,297 F1 · ownership.nature: The indirect holdings represent shares for which the Reporting Person and members of his immediate family are the sole beneficiaries. Read SEC document
November 25, 2025 Filed Nov 28, 2025 16:30 UTC	Merus N.V. MRUS · Entity 70740	GiftCommon Shares	30,297	$0.00	$0.00	Disclosure SEC source: 0001193125-25-302579 · ownership.xml · nonDerivative · entry 1 Lundberg Sven Ante · CIK 0001682126 · Director · President, CEO & PEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document
October 23, 2025 Filed Oct 28, 2025 01:34 UTC	Q32 Bio Inc. QTTB · Entity 5594	GrantStock Option (Right to Buy) · Derivative	53,521	$0.00 Strike: $2.80	$0.00	Disclosure SEC source: 0001193125-25-252000 · ownership.xml · derivative · entry 1 Lundberg Sven Ante · CIK 0001682126 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,521 Underlying: Common Stock · 53,521 shares Expires 2035-10-22 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) October 23, 2026 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. Read SEC document
May 22, 2025 Filed May 23, 2025 21:45 UTC	Vor Biopharma Inc. VOR · Entity 4763	GrantStock Option (Right to Buy) · Derivative	30,000	$0.00 Strike: $0.19	$0.00	Disclosure SEC source: 0001415889-25-014530 · form4-05232025_050511.xml · derivative · entry 1 Lundberg Sven Ante · CIK 0001682126 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-05-21 F1 · derivative.exercise_date: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) May 22, 2026 or (ii) the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document
April 17, 2025 Filed Apr 21, 2025 16:05 UTC	Merus N.V. MRUS · Entity 70740	Exercise / conversionShare Option (right to buy) · Derivative	26,500	$13.52 Strike: $13.52	$358,280.00	Disclosure SEC source: 0000950170-25-056278 · ownership.xml · derivative · entry 4 Lundberg Sven Ante · CIK 0001682126 · Director · President, CEO & PEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 312,620 Underlying: Common Shares · 26,500 shares Expires 2030-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Options vest over a four-year period from January 1, 2020. 25% vest on January 1, 2021 and in 36 equal monthly installments thereafter. Read SEC document
April 17, 2025 Filed Apr 21, 2025 16:05 UTC	Merus N.V. MRUS · Entity 70740	Exercise / conversionShare Option (right to buy) · Derivative	3,797	$12.54 Strike: $12.54	$47,614.38	Disclosure SEC source: 0000950170-25-056278 · ownership.xml · derivative · entry 3 Lundberg Sven Ante · CIK 0001682126 · Director · President, CEO & PEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 3,797 shares Expires 2029-03-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Options vest over a three-year period commencing March 19, 2019. One-third vest after one year and in 24 equal monthly installments thereafter. Read SEC document
April 17, 2025 Filed Apr 21, 2025 16:05 UTC	Merus N.V. MRUS · Entity 70740	Exercise / conversionCommon Shares	26,500	$13.52	$358,280.00	Disclosure SEC source: 0000950170-25-056278 · ownership.xml · nonDerivative · entry 2 Lundberg Sven Ante · CIK 0001682126 · Director · President, CEO & PEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,297 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 17, 2025 Filed Apr 21, 2025 16:05 UTC	Merus N.V. MRUS · Entity 70740	Exercise / conversionCommon Shares	3,797	$12.54	$47,614.38	Disclosure SEC source: 0000950170-25-056278 · ownership.xml · nonDerivative · entry 1 Lundberg Sven Ante · CIK 0001682126 · Director · President, CEO & PEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,797 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 24, 2025 Filed Feb 27, 2025 02:52 UTC	Q32 Bio Inc. QTTB · Entity 5594	GrantStock Option (Right to Buy) · Derivative	23,140	$0.00 Strike: $2.54	$0.00	Disclosure SEC source: 0000950170-25-028243 · ownership.xml · derivative · entry 12 Lundberg Sven Ante · CIK 0001682126 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,140 Underlying: Common Stock · 23,140 shares Expires 2035-01-14 F3 · derivative.exercise_price: The exercise price of the option is $2.54 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date; provided that in the event (i) the option is exercised prior to the one-year anniversary of the Repricing Date, (ii) the Reporting Person's employment is terminated by the Company prior to the one-year anniversary of the Repricing Date due to Cause (as defined in the 2024 Plan) or (iii) the Reporting Person resigns for any reason prior to the one-year anniversary of the Repricing Date, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted. F1 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document
February 24, 2025 Filed Feb 27, 2025 02:52 UTC	Q32 Bio Inc. QTTB · Entity 5594	Disposition to issuerStock Option (Right to Buy) · Derivative	23,140	$0.00 Strike: $3.20	$0.00	Disclosure SEC source: 0000950170-25-028243 · ownership.xml · derivative · entry 11 Lundberg Sven Ante · CIK 0001682126 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,140 shares Expires 2035-01-14 F1 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document
February 24, 2025 Filed Feb 27, 2025 02:52 UTC	Q32 Bio Inc. QTTB · Entity 5594	Disposition to issuerStock Option (Right to Buy) · Derivative	1,316	$0.00 Strike: $44.40	$0.00	Disclosure SEC source: 0000950170-25-028243 · ownership.xml · derivative · entry 9 Lundberg Sven Ante · CIK 0001682126 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,316 shares Expires 2034-09-24 F1 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document
February 24, 2025 Filed Feb 27, 2025 02:52 UTC	Q32 Bio Inc. QTTB · Entity 5594	GrantStock Option (Right to Buy) · Derivative	12,767	$0.00 Strike: $2.54	$0.00	Disclosure SEC source: 0000950170-25-028243 · ownership.xml · derivative · entry 8 Lundberg Sven Ante · CIK 0001682126 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,767 Underlying: Common Stock · 12,767 shares Expires 2034-03-24 F3 · derivative.exercise_price: The exercise price of the option is $2.54 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date; provided that in the event (i) the option is exercised prior to the one-year anniversary of the Repricing Date, (ii) the Reporting Person's employment is terminated by the Company prior to the one-year anniversary of the Repricing Date due to Cause (as defined in the 2024 Plan) or (iii) the Reporting Person resigns for any reason prior to the one-year anniversary of the Repricing Date, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted. F1 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document
February 24, 2025 Filed Feb 27, 2025 02:52 UTC	Q32 Bio Inc. QTTB · Entity 5594	Disposition to issuerStock Option (Right to Buy) · Derivative	12,767	$0.00 Strike: $16.82	$0.00	Disclosure SEC source: 0000950170-25-028243 · ownership.xml · derivative · entry 7 Lundberg Sven Ante · CIK 0001682126 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,767 shares Expires 2034-03-24 F1 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document
February 24, 2025 Filed Feb 27, 2025 02:52 UTC	Q32 Bio Inc. QTTB · Entity 5594	GrantStock Option (Right to Buy) · Derivative	2,880	$0.00 Strike: $2.54	$0.00	Disclosure SEC source: 0000950170-25-028243 · ownership.xml · derivative · entry 6 Lundberg Sven Ante · CIK 0001682126 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,880 Underlying: Common Stock · 2,880 shares Expires 2031-01-21 F3 · derivative.exercise_price: The exercise price of the option is $2.54 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date; provided that in the event (i) the option is exercised prior to the one-year anniversary of the Repricing Date, (ii) the Reporting Person's employment is terminated by the Company prior to the one-year anniversary of the Repricing Date due to Cause (as defined in the 2024 Plan) or (iii) the Reporting Person resigns for any reason prior to the one-year anniversary of the Repricing Date, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted. F1 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document
February 24, 2025 Filed Feb 27, 2025 02:52 UTC	Q32 Bio Inc. QTTB · Entity 5594	Disposition to issuerStock Option (Right to Buy) · Derivative	2,880	$0.00 Strike: $7.29	$0.00	Disclosure SEC source: 0000950170-25-028243 · ownership.xml · derivative · entry 5 Lundberg Sven Ante · CIK 0001682126 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,880 shares Expires 2031-01-21 F1 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document
February 24, 2025 Filed Feb 27, 2025 02:52 UTC	Q32 Bio Inc. QTTB · Entity 5594	GrantStock Option (Right to Buy) · Derivative	6,238	$0.00 Strike: $2.54	$0.00	Disclosure SEC source: 0000950170-25-028243 · ownership.xml · derivative · entry 4 Lundberg Sven Ante · CIK 0001682126 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,238 Underlying: Common Stock · 6,238 shares Expires 2028-12-06 F3 · derivative.exercise_price: The exercise price of the option is $2.54 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date; provided that in the event (i) the option is exercised prior to the one-year anniversary of the Repricing Date, (ii) the Reporting Person's employment is terminated by the Company prior to the one-year anniversary of the Repricing Date due to Cause (as defined in the 2024 Plan) or (iii) the Reporting Person resigns for any reason prior to the one-year anniversary of the Repricing Date, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted. F1 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document
February 24, 2025 Filed Feb 27, 2025 02:52 UTC	Q32 Bio Inc. QTTB · Entity 5594	Disposition to issuerStock Option (Right to Buy) · Derivative	6,238	$0.00 Strike: $3.13	$0.00	Disclosure SEC source: 0000950170-25-028243 · ownership.xml · derivative · entry 3 Lundberg Sven Ante · CIK 0001682126 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,238 shares Expires 2028-12-06 F1 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document
February 24, 2025 Filed Feb 27, 2025 02:52 UTC	Q32 Bio Inc. QTTB · Entity 5594	GrantStock Option (Right to Buy) · Derivative	2,013	$0.00 Strike: $2.54	$0.00	Disclosure SEC source: 0000950170-25-028243 · ownership.xml · derivative · entry 2 Lundberg Sven Ante · CIK 0001682126 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,013 Underlying: Common Stock · 2,013 shares Expires 2028-12-06 F3 · derivative.exercise_price: The exercise price of the option is $2.54 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date; provided that in the event (i) the option is exercised prior to the one-year anniversary of the Repricing Date, (ii) the Reporting Person's employment is terminated by the Company prior to the one-year anniversary of the Repricing Date due to Cause (as defined in the 2024 Plan) or (iii) the Reporting Person resigns for any reason prior to the one-year anniversary of the Repricing Date, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted. F1 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document
February 24, 2025 Filed Feb 27, 2025 02:52 UTC	Q32 Bio Inc. QTTB · Entity 5594	Disposition to issuerStock Option (Right to Buy) · Derivative	2,013	$0.00 Strike: $3.13	$0.00	Disclosure SEC source: 0000950170-25-028243 · ownership.xml · derivative · entry 1 Lundberg Sven Ante · CIK 0001682126 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,013 shares Expires 2028-12-06 F1 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document
February 19, 2025 Filed Feb 21, 2025 16:05 UTC	Merus N.V. MRUS · Entity 70740	GiftCommon Shares	40,601	$0.00	$0.00	Disclosure SEC source: 0000950170-25-024836 · ownership.xml · nonDerivative · entry 2 Lundberg Sven Ante · CIK 0001682126 · Director · President, CEO & PEO 10b5-1 filing: No plan indicated Ownership: Indirect · Ante S Lundberg Qualified Annuity Int Trust X Disclosed balance after: 40,601 F1 · date: On February 19, 2025, the reporting person transferred 40,601 shares of Issuer common shares to a family trust of which the reporting person is trustee. The reporting person and members of his immediate family are the sole beneficiaries of the trust Read SEC document
February 19, 2025 Filed Feb 21, 2025 16:05 UTC	Merus N.V. MRUS · Entity 70740	GiftCommon Shares	40,601	$0.00	$0.00	Disclosure SEC source: 0000950170-25-024836 · ownership.xml · nonDerivative · entry 1 Lundberg Sven Ante · CIK 0001682126 · Director · President, CEO & PEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · date: On February 19, 2025, the reporting person transferred 40,601 shares of Issuer common shares to a family trust of which the reporting person is trustee. The reporting person and members of his immediate family are the sole beneficiaries of the trust Read SEC document
February 13, 2025 Filed Feb 18, 2025 17:43 UTC	Merus N.V. MRUS · Entity 70740	Exercise / conversionShare Option (right to buy) · Derivative	16,372	$0.00 Strike: $24.43	$0.00	Disclosure SEC source: 0000950170-25-022520 · ownership.xml · derivative · entry 2 Lundberg Sven Ante · CIK 0001682126 · Director · President, CEO & PEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 351,628 Underlying: Common Shares · 16,372 shares Expires 2031-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Options vest over a four-year period from January 1, 2021. 25% vest on January 1, 2022 and in 36 equal monthly installments thereafter. Read SEC document
February 13, 2025 Filed Feb 18, 2025 17:43 UTC	Merus N.V. MRUS · Entity 70740	Exercise / conversionCommon Shares	16,372	$24.43	$399,967.96	Disclosure SEC source: 0000950170-25-022520 · ownership.xml · nonDerivative · entry 1 Lundberg Sven Ante · CIK 0001682126 · Director · President, CEO & PEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,601 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 29, 2025 Filed Jan 31, 2025 16:31 UTC	Merus N.V. MRUS · Entity 70740	GrantShare Option (right to buy) · Derivative	300,000	$0.00 Strike: $41.65	$0.00	Disclosure SEC source: 0000950170-25-011796 · ownership.xml · derivative · entry 1 Lundberg Sven Ante · CIK 0001682126 · Director · President, CEO & PEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Shares · 300,000 shares Expires 2035-01-29 F1 · derivative.exercise_date: Options vest over a four-year period from January 1, 2025. 25% vest on January 1, 2026 and in 36 equal monthly installments thereafter. Read SEC document
January 15, 2025 Filed Feb 27, 2025 02:52 UTC	Q32 Bio Inc. QTTB · Entity 5594	GrantStock Option (Right to Buy) · Derivative	23,140	$0.00 Strike: $3.20	$0.00	Disclosure SEC source: 0000950170-25-028243 · ownership.xml · derivative · entry 10 Lundberg Sven Ante · CIK 0001682126 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,140 Underlying: Common Stock · 23,140 shares Expires 2035-01-14 F4 · kind: This option was granted to the Reporting Person, a director of the Issuer pursuant to the 2024 Plan and pursuant to the Issuer's non-employee director compensation policy. This option represents the Reporting Person's election to receive stock options in lieu of cash retainer fees Due to administrative oversight this option award initially was not reported. F1 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F4 · derivative.exercise_date: This option was granted to the Reporting Person, a director of the Issuer pursuant to the 2024 Plan and pursuant to the Issuer's non-employee director compensation policy. This option represents the Reporting Person's election to receive stock options in lieu of cash retainer fees Due to administrative oversight this option award initially was not reported. Read SEC document
September 25, 2024 Filed Sep 28, 2024 01:57 UTC	Q32 Bio Inc. QTTB · Entity 5594	GrantStock Option (Right to Buy) · Derivative	1,316	$0.00 Strike: $44.40	$0.00	Disclosure SEC source: 0000950170-24-110150 · ownership.xml · derivative · entry 1 Lundberg Sven Ante · CIK 0001682126 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,316 Underlying: Common Stock · 1,316 shares Expires 2034-09-24 F1 · derivative.exercise_date: The shares underlying this option vest in three equal quarterly installments on each of June 30, 2024, September 30, 2024 and December 31, 2024. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.